Status:

TERMINATED

Standardized Vascular Rehabilitation Program to Improve Patient Disease and Quality of Life

Lead Sponsor:

Baylor Research Institute

Conditions:

Vascular Diseases

Peripheral Artery Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to identify the type of patients being referred for the Vascular Rehabilitation Program (VRP) and to study the success rates of the program according to improvements in wa...

Detailed Description

Peripheral arterial occlusive disease (PAOD) affects 8.5 million people in the United States. One of the most common symptoms of PAOD is claudication. While there are surgical and endovascular treatme...

Eligibility Criteria

Inclusion

  • Enrolled in the vascular rehabilitation program at The Heart Hospital Cardiac Rehabilitation Facility.
  • Female or male patients ≥18 years of age.
  • Patient must be accessible for treatment and follow-up.
  • Agrees to wear the activity tracker wrist-worn device
  • Agrees to the follow-up QOL survey schedule
  • Agrees to the follow-up ABI schedule
  • All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry.

Exclusion

  • Declines participation in the study.
  • Has a life-expectancy less than 18 months.
  • Unable to complete necessary study follow-up procedures.
  • Unwilling to wear the wrist-worn activity tracker device.
  • Women who are pregnant.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as:
  • severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
  • home oxygen
  • neurologic or orthopedic conditions limiting ability to appropriately comply with rehabilitation program.
  • class III or class IV NY class congestive heart failure
  • Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

Key Trial Info

Start Date :

December 13 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 24 2022

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT04335695

Start Date

December 13 2019

End Date

January 24 2022

Last Update

October 14 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Baylor Scott & White Heart Hospital- Plano

Plano, Texas, United States, 75093